Evidence map›Paper›PMID 34595446›Full record

ArticleClinical hematology international2020

The CD34

M Remberger, B Grønvold, M Ali, J Mattsson, T Egeland, K U Lundin, A Myhre, I Abrahamsen, D Heldal, I Dybedal and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical hematology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Impact of CD34British journal of haematology · 2026
    Article
  2. Article
  3. Impact of CD34Blood research · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

M RembergerDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
B GrønvoldDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
M AliDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
J MattssonHans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
T EgelandDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
K U LundinDepartment of Immunology, Oslo University Hospital, Oslo, Norway.
A MyhreDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
I AbrahamsenDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
D HeldalDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
I DybedalDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
G E TjønnfjordDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
T Gedde-DahlDepartment of Hematology, Oslo University Hospital, Oslo, Norway.
Y FløisandDepartment of Hematology, Oslo University Hospital, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effect of CD34

Indexed as

CD34Cell doseGVHDHSCTPBSC

Identifiers

PMID34595446
PMCPMC8432346

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.